Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C

Vigani, Aline Gonzalez; Pavan, Maria H.P.; Tozzo, Raquel; Gonçales, Eduardo S.L.; Lazarini, Maria S.K.; de Oliveira, Alexandre Macedo; Gonçales, Fernando L.

doi:10.1016/S1413-8670(10)70038-6

The Brazilian Journal of Infectious Diseases

ISSN: 1413-8670

The Brazilian Journal of Infectious Diseases is the official publication of the Brazilian Society of Infectious Diseases (SBI). It aims to publish relevant articles in the broadest sense on all aspects of microbiology, infectious diseases and immune response to infectious agents.
The BJID is a bimonthly publication and one of the most influential journals in its field in Brazil and Latin America with a high impact factor. Since its inception it has garnered a growing share of the publishing market.

Indexed in:

CABI Publishing; Chemical Abstracts (CAS); China Education Publications Import and Export Corporation (CEPIEC); EBSCO Database (Premium Research); Elsevier Science - Bibliographic Databases Division; Embase/Excerpta Medica; Gale Cengage Learning; Index Copernicus International; ISI (Web of Science) - Science Citation Index Expanded (SCISEARCH); Journal Citation Reports (Science Edition); Kessler-Hancok Information Service; Latin America and Caribean Literature of Health Science (LILACS); LATINDEX; Medline/ Index Medicus/Pubmed; Qualis International (CAPES): B3 (International Quality); Redalyc (Network of Scientific Journals of Latin America, Caribbean, Spain and Portugal) SCIELO; SCIRUS (Elsevier); SCOPUS Index; Sociedad Iberoamericana de Información Cientifica (SIIC); Subis Database (SUBIS Bulletin); Swets Blackwell; Teldan Database Production; The US Library of Congress Office; Ulrich¿s Periodicals Directory.

Hemodialysis patient with chronic HCV infection, who was started on monotherapy with interferon. Qualitative HCV RNA remained positive at 12 weeks of treatment; ribavirin was associated. HCV RNA was negative at week 24 and treatment was extended to 72 weeks. HCV RNA negative six months after treatment.

Keywords:

hepatitis C virus

hemodialysis

treatment

interferon

ribavirin

Full text is only aviable in PDF

References

[1.]

C.E. Gordon, K. Uhlig, J. Lau, C.H. Schmid, A.S. Levey, J.B. Wong.

Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms.

Am J Kidney Dis., 51 (2008), pp. 263-277

http://dx.doi.org/10.1053/j.ajkd.2007.11.003 | Medline

[2.]

P. Dattolo, M. Lombardi, G. Ferro, S. Michelassi, T. Cerrai, F. Pizzarelli.

Natural history of HCV infection and risk of death in a cohort of patients on long-term hemodialysis.

G Ital Nefrol., 23 (2006), pp. 585-590

Medline

[3.]

F. Fabrizi, P. Martin, V. Dixit, S. Bunnapradist, G. Dulai.

Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies.

Am J Transplant., 5 (2005), pp. 1452-1461

http://dx.doi.org/10.1111/j.1600-6143.2005.00864.x | Medline

[4.]

D. Carriero, F. Fabrizi, A.J. Uriel, J. Park, P. Martin, D.T. Dieterich.

Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.

Int J Artif Organs., 31 (2008), pp. 295-302

Medline

[5.]

E. Nakayama, T. Akiba, F. Marumo, C. Sato.

Prognosis of antihepatitis C virus antibody-positive patients on regular hemodialysis therapy.

J Am Soc Nephrol., 11 (2000), pp. 1896-1902

Medline

[6.]

E. Gane, H. Pilmore.

Management of chronic viral hepatitis before and after renal transplantation.

Transplantation, 74 (2002), pp. 427-437

http://dx.doi.org/10.1097/01.TP.0000020756.34168.E0 | Medline

[7.]

P. Mathurin, C. Mouquet, T. Poynard, C. Sylla, H. Benalia, C. Fretz, et al.

Impact of hepatitis B and C virus on kidney transplantation outcome.

Hepatology, 29 (1999), pp. 257-263

http://dx.doi.org/10.1002/hep.510290123 | Medline

[8.]

G.A. Knoll, M.R. Tankersley, J.Y. Lee, B.A. Julian, J.J. Curtis.

The impact of renal transplantation on survival in hepatitis C-positive endstage renal disease patients.

Am J Kidney Dis., 29 (1997), pp. 608-614

Medline

[9.]

N. Kamar, O. Toupance, M. Buchler, K. Sandres-Saune, J. Izopet, D. Durand, et al.

Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation.

J Am Soc Nephrol., 14 (2003), pp. 2092-2098

Medline

[10.]

F. Fabrizi, G. Dulai, V. Dixit, S. Bunnapradist, P. Martin.

Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients.

Aliment Pharmacol Ther., 18 (2003), pp. 1071-1081

Medline

[11.]

M.W. Russo, C.D. Goldsweig, I.M. Jacobson, R.S. Brown Jr.

Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.

Am J Gastroenterol., 98 (2003), pp. 1610-1615

http://dx.doi.org/10.1111/j.1572-0241.2003.07526.x | Medline

[12.]

P. Glue.

The clinical pharmacology of ribavirin.

Semin Liver Dis., 19 (1999), pp. 17-24

Medline

[13.]

M. Rendina, A. Schena, N.M. Castellaneta, F. Losito, A.C. Amoruso, G. Stallone, et al.

The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.

J Hepatol., 46 (2007), pp. 768-774

http://dx.doi.org/10.1016/j.jhep.2006.12.016 | Medline

[14.]

A. Bruchfeld, L. Ståhle, J. Andersson, R. Schvarcz.

Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study.

J Viral Hepat., 8 (2001), pp. 287-292

Medline

[15.]

F. Fabrizi, F.F. Poordad, P. Martin.

Hepatitis C infection and the patient with end-stage renal disease.

Hepatology, 36 (2002), pp. 3-10

http://dx.doi.org/10.1053/jhep.2002.34613 | Medline

[16.]

S. Pol, F. Carnot, B. Nalpas, J.L. Lagneau, H. Fontaine, J. Serpaggi, L. Serfaty, P. Bedossa, C. Bréchot.

Reversibility of hepatitis C virus-related cirrhosis.

Hum Pathol., 35 (2004), pp. 107-112

Medline

[17.]

S. Maylin, M. Martinot-Peignoux, R. Moucari, N. Boyer, M.P. Ripault, D. Cazals-Hatem, et al.

Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

Gastroenterology, 135 (2008), pp. 821-829

http://dx.doi.org/10.1053/j.gastro.2008.05.044 | Medline

[18.]

U. Mihm, E. Herrmann, C. Sarrazin, S. Zeuzem.

Review article: predicting response in hepatitis C virus therapy.

Aliment Pharmacol Ther., 23 (2006), pp. 1043-1054

http://dx.doi.org/10.1111/j.1365-2036.2006.02863.x | Medline

[19.]

T. Berg, M. von Wagner, S. Nasser, C. Sarrazin, T. Heintges, T. Gerlach, et al.

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Gastroenterology, 130 (2006), pp. 1086-1097

http://dx.doi.org/10.1053/j.gastro.2006.02.015 | Medline

Indexed in:

Follow us:

Subscribe to our newsletter